Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral

of NHS resources. Aspirin plus rivaroxaban is therefore recommended as a treatment option for people at high risk of having atherothrombotic events, who are not identified as having an increased risk of bleeding. 2 Information about rivaroxaban Marketing authorisation indication 2.1 Rivaroxaban (Xarelto, Bayer), co-administered with aspirin, is indicated for 'the prevention of atherothrombotic events in adult patients with coronary artery disease or symptomatic peripheral artery disease at high risk of ischaemic events'. Dosage in the marketing authorisation 2.2 The recommended dosage for rivaroxaban is 2.5 mg taken orally twice daily in combination with a daily dose of 75 to 100 mg aspirin taken orally. Price 2.3 The list price for 56 tablets of rivaroxaban 2.5 mg is £50.40 (company submission). The treatment period is indefinite. 3 Committee discussion The appraisal committee considered evidence submitted by Bayer, a review of this submission by the evidence review group (ERG), and the technical report developed through engagement with stakeholders. See the committee papers for full details of the evidence. The appraisal committee was aware that several issues were resolved during the technical engagement stage, and agreed that: • It is more clinically plausible to substitute transition probability values used in the economic
